The DOI matches its Crossref record; 164 of the 165 references it cites were found in a registry or an index.
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
Open accessAbstract
Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximately 31.4% of deaths globally in 2012. It is estimated that, from 1980 to 2000, reduction in total cholesterol accounted for a 33% decrease in coronary heart disease (CHD) deaths in the United States. In other developed countries, similar decreases in CHD deaths (ranging from 19%-46%) have been attributed to reduction in total cholesterol. Low-density lipoprotein cholesterol (LDL-C) has now largely replaced total cholesterol as a risk marker and the primary treatment target for hyperlipidemia. Reduction in LDL-C levels by statin-based therapies has been demonstrated to result in a reduction in the risk of nonfatal CV events and mortality in a continuous and graded manner over a wide range of baseline risk and LDL-C levels. This article provides a review of (1) the relationship between LDL-C and CV risk from a biologic, epidemiologic, and genetic standpoint; (2) evidence-based strategies for LDL-C lowering; (3) lipid-management guidelines; (4) new strategies to further reduce CV risk through LDL-C lowering; and (5) population-level and health-system initiatives aimed at identifying, treating, and lowering lifetime LDL-C exposure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, where TC and LDL-C are elevated at baseline, a statistical effect is evident following exercise but the magnitude of the changes may not be clinically important [141, 142].”
From Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis (2019) · cites this paper as [142]
In the citing paper
“Our findings thus potentially explain the reported APOE genotype effects on human plasma LDL levels”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [53]
In the citing paper
“a profile that correlates with lower cardiovascular disease risk53.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [53]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Cited by
Sorted by citations
Items 301–306 of 306
Assaad, A. A. (2023) · theses.fr (ABES) · doi:10.70675/d21af1f0z83eaz4ec6z8b74z6815eb479999
Detection of previously undiagnosed conditions in midlife preventive health examinations
Kalski, L., Hafermann, L., Caliman, T. J. P., Greiß, F., Karathanos, A., Pächter, C., Herrmann, C., & Wolfarth, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-53658-2
Huo, Y., Dejmek, J. S., Yuan, Z., Peng, D., Mena-Madrazo, J. A., Liu, K. X., Zhang, M., Ji, Y., Xing, X., Yao, Z., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.016
Barakat, H. E., Abougalambou, A. S., Maher, W., Nour, S. M., Abdelhalim, I. T., Binsaleh, A. Y., Belal, D. M. I., & Abougalambou, S. S. I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1870914
Lipid-Lowering Therapy Preferences in the LISTEN-LDL-US Study
Nanna, M. G., Victores, A., Snyder, K., Bash, L. D., Krupsky, K. L., McCaig, E., King-Concialdi, K., Beusterien, K., Matta, J., Brault, M. W., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103107
BindingDB (2021) · UC San Diego · doi:10.7270/q2j38wzz
Metadata
- Authors
- Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Cincinnati (US)
- Sanofi (United States) (US)
- Corresponding author
- Wadhera, Rishi K.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 10
- Issue
- 3
- Pages
- 472-489
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W2183544076
- Cited by
- 306
- References
- 165
- Citations by year
- 2026: 7 · 2025: 26 · 2024: 27 · 2023: 40 · 2022: 32 · 2021: 31 · 2020: 35 · 2019: 38 · 2018: 34 · 2017: 26 · 2016: 8
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of clinical lipidology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Regeneron Pharmaceuticals
- International Atherosclerosis Society
- European Atherosclerosis Society
- Daiichi-Sankyo
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- LDL cholesterol, cardiovascular disease, hyperlipidemia, statin therapy, LDL cholesterol lowering, cardiovascular risk, coronary heart disease mortality, cardiovascular risk reduction, total cholesterol
- MeSH terms
- Animals, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Life Style, Cholesterol, LDL, Risk, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
